Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,739,540
  • Shares Outstanding, K 66,344
  • Annual Sales, $ 6,880 K
  • Annual Income, $ -141,430 K
  • EBIT $ -174 M
  • EBITDA $ -177 M
  • 60-Month Beta 1.60
  • Price/Sales 254.46
  • Price/Cash Flow N/A
  • Price/Book 2.23

Options Overview Details

View History
  • Implied Volatility 59.03% ( -8.31%)
  • Historical Volatility 56.06%
  • IV Percentile 57%
  • IV Rank 23.73%
  • IV High 116.13% on 09/17/24
  • IV Low 41.26% on 06/24/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 44
  • Volume Avg (30-Day) 239
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 18,504
  • Open Int (30-Day) 27,100

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.87
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -29.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.93 +17.84%
on 11/18/24
29.38 -8.03%
on 10/28/24
-1.74 (-6.05%)
since 10/22/24
3-Month
22.93 +17.84%
on 11/18/24
47.00 -42.51%
on 09/25/24
-8.26 (-23.41%)
since 08/22/24
52-Week
22.93 +17.84%
on 11/18/24
53.18 -49.19%
on 03/04/24
-0.73 (-2.63%)
since 11/22/23

Most Recent Stories

More News
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation

Celldex Therapeutics began Phase 1a study of CDX-622, targeting chronic inflammation through a bispecific antibody approach.Quiver AI SummaryCelldex Therapeutics, Inc. has announced the commencement of...

CLDX : 27.02 (+3.05%)
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

CLDX : 27.02 (+3.05%)
Celldex Therapeutics to Present at Upcoming Investor Conferences

CLDX : 27.02 (+3.05%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 27.02 (+3.05%)
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

CLDX : 27.02 (+3.05%)
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

CLDX : 27.02 (+3.05%)
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

CLDX : 27.02 (+3.05%)
Can This Growth Stock Deliver 135% Upside in 2025?

Positive clinical trial results have sparked hope for this biotech.

CLDX : 27.02 (+3.05%)
$SPX : 5,969.34 (+0.35%)
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for...

CLDX : 27.02 (+3.05%)
KRYS : 190.40 (+4.45%)
FULC : 3.25 (+9.43%)
ANIP : 56.91 (+1.88%)
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 27.02 (+3.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 28.58
2nd Resistance Point 27.86
1st Resistance Point 27.44
Last Price 27.02
1st Support Level 26.30
2nd Support Level 25.58
3rd Support Level 25.16

See More

52-Week High 53.18
Fibonacci 61.8% 41.62
Fibonacci 50% 38.05
Fibonacci 38.2% 34.48
Last Price 27.02
52-Week Low 22.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar